Garry E Menzel
CIK 1556064 · President and CEO · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TCRR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
45 WIGGINS AVENUE
BEDFORD, MA 01730
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BDTX | Director | 51,825 | $1.69 | $87.3K | $0 | 8 | 2026-06-29 |
| STOK | Director | — | $25.50 | — | $0 | 6 | 2025-06-04 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 275,703 | $0.06 | $16.0K | -$43.4K | 5 | 2024-07-01 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | President and CEO | 0 | $1.48 | $0 | -$101.9K | 15 | 2023-06-01 |
| DVA | Senior Vice President, Finance | — | $182.15 | — | $0 | 1 | 2013-09-11 |
| Regulus Therapeutics Inc. (RGLS) Delisted | COO & Executive VP, Finance | — | $8.16 | — | $0 | 1 | 2012-12-13 |
Recent Filings · Page 3 of 4
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-13 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2022-06-08 | STOK | Grant (A) | — | $0 | EDGAR |
| 2022-03-18 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | +1,425 | $3.3K | EDGAR |
| 2021-12-10 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Mixed | +175,422 | $135.5K | EDGAR |
| 2021-06-25 | STOK | Grant (A) | — | $0 | EDGAR |
| 2021-06-22 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2021-04-23 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2021-03-08 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | +1,818 | $22.5K | EDGAR |
| 2021-01-27 | STOK | Grant (A) | — | $0 | EDGAR |
| 2020-12-11 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.